HighTower Advisors LLC Sells 2,967 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

HighTower Advisors LLC decreased its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 12.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 20,278 shares of the company’s stock after selling 2,967 shares during the quarter. HighTower Advisors LLC’s holdings in Intellia Therapeutics were worth $415,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in NTLA. Blue Trust Inc. boosted its position in Intellia Therapeutics by 1,664.3% in the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after buying an additional 1,398 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Intellia Therapeutics by 763.5% during the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock worth $39,000 after buying an additional 1,550 shares in the last quarter. Eastern Bank bought a new position in shares of Intellia Therapeutics in the third quarter valued at approximately $41,000. Values First Advisors Inc. acquired a new position in shares of Intellia Therapeutics in the 3rd quarter worth approximately $54,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Intellia Therapeutics by 27.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock worth $77,000 after acquiring an additional 794 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Insiders Place Their Bets

In related news, CAO Michael P. Dube sold 2,012 shares of the company’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the transaction, the chief accounting officer now directly owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. This represents a 4.10 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.20% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on NTLA. Stifel Nicolaus cut their price objective on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a research report on Wednesday, September 11th. Robert W. Baird cut their price target on Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating for the company in a report on Friday, October 25th. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a report on Friday, November 8th. Barclays dropped their target price on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Finally, Wedbush reissued a “neutral” rating and set a $14.00 price target on shares of Intellia Therapeutics in a research note on Monday, November 18th. One research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Intellia Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $54.94.

Intellia Therapeutics Stock Up 0.8 %

Shares of NTLA stock opened at $12.18 on Friday. The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of -2.24 and a beta of 1.76. Intellia Therapeutics, Inc. has a 12-month low of $11.79 and a 12-month high of $34.87. The firm has a fifty day moving average of $15.59 and a 200-day moving average of $20.26.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.28 million. During the same period in the prior year, the business earned ($1.38) EPS. The company’s revenue for the quarter was down 24.1% compared to the same quarter last year. Research analysts expect that Intellia Therapeutics, Inc. will post -5.12 earnings per share for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.